Form 4: Avidity Biosciences Director Levin Exercises Options and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On July 19, 2024, Arthur A. Levin, a director of Avidity Biosciences, Inc., exercised options to purchase 5,000 shares of common stock at a price of $1.24 per share.
  • Simultaneously, Levin sold 5,000 shares of common stock at a weighted-average price of $45.0138, with individual sales ranging from $44.20 to $45.38.
  • These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on May 26, 2023.
  • Following these transactions, Levin directly owns 14,830 shares and indirectly owns 153,872 shares through a family trust.
  • Levin also directly owns 18,323 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, allowing investors to monitor potential alignment or misalignment of interests.

Key Dates

DateDescription
2023-05-26Date the Reporting Person adopted a Rule 10b5-1 trading plan
2024-07-19Date of option exercise and stock sale
2030-02-18Expiration date of stock options
2024-07-23Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.